How AbbVie's Pipeline Is Lining Up Key Product Launches

Key Takeaways AbbVie is advancing Rinvoq expansions, tavapadon and PVEK toward multiple potential product launches.Rinvoq label expansions across five indications could add roughly $2B to peak-year sales.Tavapadon and PVEK are under FDA review as AbbVie expands its pipeline via acquisitions.AbbVie (ABBV) has been consistently increasing its R&D investments to support long-term growth across multiple therapeutic areas. The company’s pipeline spans immunology therapies, expanding oncology programs and innovat ...